Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus

Journal of Women's Health

Volumn 18, Issue 9, 2009, Pages 1435-1439

  Camuzcuoglu, Hakan ^a   Toy, Harun ^a   Cakir, Hale ^a   Celik, Hakim ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PATHOGENESIS; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CORONARY ARTERY DISEASE; DIABETES, GESTATIONAL; FEMALE; HUMANS; OXIDATIVE STRESS; PREGNANCY; REFERENCE VALUES; YOUNG ADULT;

EID: 70349196190     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2008.1213     Document Type: Article

References (37)

1. American Diabetes Association. Standards of medical care in diabetes [Position Statement]. Diabetes Care 2005;28:S4-S36.
2. Gabbe SG. Gestational diabetes mellitus. N Engl J Med 1986;315:1025-1026.
3. Coughlana MT, Vervaartb PP, Permezela M, et al. Altered placental oxidative stress status in gestational diabetes mellitus. Placenta 2004;25:78-84.
4. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-1868.
5. Toescu V, Nuttall SL, Martin U, et al. Changes in plasma lipids and markers of oxidative stress in normal pregnancy and pregnancies complicated by diabetes. Clin Sci 2004; 106:93-98.
6. Carew TE. Role of biologically modified low-density lipoprotein in atherosclerosis. Am J Cardiol 1989;64:18G-22G.
7. Yildiz A, Gur M, Yilmaz R, et al. Association of paraoxonase activity and coronary blood flow. Atherosclerosis 2008; 197:257-263.
8. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998;39: 1529-1542.
9. Barter PJ, Rye KA. High-density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.
10. Canales A, Sanchez-Muniz FJ. Paraoxanase, something more than an enzyme? Med Clin (Barc) 2003;121:537-548.
11. Blatter MC, James RW, Messmer S, et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993;211:871-879.
12. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high-density lipoprotein-associated paraoxonase. Inhibition of the biological activity of minimally oxidized low-density lipoprotein. J Clin Invest 1995;96:2882-2891.
13. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-1590.
14. Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:330-335.
15. Graner M, James RW, Kahri J, et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006;47:2429-2435. (Pubitemid 43866362)
16. Gur M, Aslan M, Yildiz A, et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006;36:779-787.
17. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-1457.
18. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86:193-199.
19. Paragh G, Seres I, Balogh Z, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998;80:166-170.
20. Patel BN, Mackness MI, Harty DW, et al. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim. Biophys. Acta 1990;1035:113-116.
21. American Diabetes Association. Clinical practice recommendations for gestational diabetes mellitus. Diabetes Care 2001;24:S77-S79.
22. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982;144:768-773.
23. Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
24. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem 1992;30:391-395.
25. Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999;300:58-62.
26. Kharb S. Lipid peroxidation in pregnancy with preeclampsia and diabetes. Gynecol Obstet Invest 1990;50:113-116.
27. Witzum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-1792.
28. Mackness B, Hunt R, Durrington PN, et al. Increased immunolocalization of paraoxonase, clusterin and polipoproteins A-I in the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:1233-1238.
29. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase and coronary heart disease. Curr Opin Lipidol 1998;9:319-324.
30. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004;4: 211-217.
31. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000;275:17527-17535.
32. Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-267.
33. Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005;181:9-18.
34. Ness RB, Harris T, Cobb J, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med 1993;328:1528-1533. (Pubitemid 23147782)
35. Lawlor DA, Emberson JR, Ebrahim S, et al. Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associ ated with child-rearing? Findings from the British Women's Heart and Health Study and the British Regional Heart Study. Circulation 2003;107:1260-1264.
36. Wollf B, Völzke H, Robinson D, et al. Relation of parity with common carotid intima media thickness among women of the Study of Health in Pomerania. Stroke 2005;36:938-943.
37. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 2002;325:157-160.